Grace Smith

Dr. Grace Smith

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BSBenjamin D. Smith
Benjamin D. Smith
GSGrace Smith
Grace Smith
AHArti Hurria
Arti Hurria
GHGabriel N. Hortobagyi
Gabriel N. Hortobagyi
TBThomas A. Buchholz
Thomas A. Buchholz
Purpose: By 2030, the United States' population will increase to approximately 365 million, including 72 million older adults (age ≥ 65 years) and 157 million minority individuals. Although cancer incidence varies by age and race, the impact of demographic changes on cancer incidence has not been fully characterized. We sought to estimate the number of cancer patients diagnosed in the United States through 2030 by age and race. Methods: Current demographic-specific cancer incidence rates were calculated using the Surveillance Epidemiology and End Results database. Population projections from the Census Bureau were used to project future cancer incidence through 2030. Results: From 2010 to 2030, the total projected cancer incidence will increase by approximately 45%, from 1.6 million in 2010 to 2.3 million in 2030. This increase is driven by cancer diagnosed in older adults and minorities. A 67% increase in cancer incidence is anticipated for older adults, compared with an 11% increase for younger adults. A 99% increase is anticipated for minorities, compared with a 31% increase for whites. From 2010 to 2030, the percentage of all cancers diagnosed in older adults will increase from 61% to 70%, and the percentage of all cancers diagnosed in minorities will increase from 21% to 28%. Conclusion: Demographic changes in the United States will result in a marked increase in the number of cancer diagnoses over the next 20 years. Continued efforts are needed to improve cancer care for older adults and minorities.

1 May 2006 in JACC
Verified
Journal Article
Closed access
GSGrace Smith
Grace Smith
JLJudith H. Lichtman
Judith H. Lichtman
MBMichael B. Bracken
Michael B. Bracken
MSMichael G. Shlipak
Michael G. Shlipak
CPChristopher O. Phillips
Christopher O. Phillips
HKHarlan M. Krumholz
Harlan M. Krumholz

1 January 2002 in JACC
Verified
Journal Article
Closed access
HKHarlan M Krumholz
Harlan M Krumholz
JAJoan Amatruda
Joan Amatruda
GSGrace Smith
Grace Smith
JMJennifer A Mattera
Jennifer A Mattera
SRSarah A Roumanis
Sarah A Roumanis
VVViola Vaccarino
Viola Vaccarino

1 October 2019 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
GSGrace Smith
Grace Smith
MLMaria A. Lopez-Olivo
Maria A. Lopez-Olivo
PAPragati G. Advani
Pragati G. Advani
MNMatthew S. Ning
Matthew S. Ning
YGYimin Geng
Yimin Geng
RVRobert J. Volk
Robert J. Volk
Background: Patients with cancer experience financial toxicity from the costs of treatment, as well as material and psychologic stress related to this burden. A synthesized understanding of predictors and outcomes of the financial burdens associated with cancer care is needed to underpin strategic responses in oncology care. This study systematically reviewed risk factors and outcomes associated with financial burdens related to cancer treatment. Methods: MEDLINE, Embase, PubMed, PsychINFO, and the Cochrane Library were searched from study inception through June 2018, and reference lists were scanned from studies of patient-level predictors and outcomes of financial burdens in US patients with cancer (aged ≥18 years). Two reviewers conducted screening, abstraction, and quality assessment. Variables associated with financial burdens were synthesized. When possible, pooled estimates of associations were calculated using random-effects models. Results: A total of 74 observational studies of financial burdens in 598,751 patients with cancer were identified, among which 49% of patients reported material or psychologic financial burdens (95% CI, 41%–56%). Socioeconomic predictors of worse financial burdens with treatment were lack of health insurance, lower income, unemployment, and younger age at cancer diagnosis. Compared with patients with health insurance, those who were uninsured demonstrated twice the odds of financial burdens (pooled odds ratio [OR], 2.09; 95% CI, 1.33–3.30). Financial burdens were most severe early in cancer treatment, did not differ by disease site, and were associated with worse health-related quality of life (HRQoL) and nearly twice the odds of cancer medication nonadherence (pooled OR, 1.70; 95% CI, 1.13–2.56). Only a single study demonstrated an association with increased mortality. Studies assessing the comparative effectiveness of interventions to mitigate financial burdens in patients with cancer were lacking. Conclusions: Evidence showed that financial burdens are common, disproportionately impacting younger and socioeconomically disadvantaged patients with cancer, across disease sites, and are associated with worse treatment adherence and HRQoL. Available evidence helped identify vulnerable patients needing oncology provider engagement and response, but evidence is critically needed on the effectiveness of interventions designed to mitigate financial burden and impact.

1 January 2003 in JACC
Verified
Journal Article
Closed access
FMFrederick A Masoudi
Frederick A Masoudi
EHEdward P Havranek
Edward P Havranek
GSGrace Smith
Grace Smith
RFRonald H Fish
Ronald H Fish
JSJohn F Steiner
John F Steiner
HKHarlan M Krumholz
Harlan M Krumholz

1 February 2003 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
PDF file
GSGrace Smith
Grace Smith
VVViola Vaccarino
Viola Vaccarino
MKMikhail Kosiborod
Mikhail Kosiborod
JLJudith H. Lichtman
Judith H. Lichtman
SCSusan Cheng
Susan Cheng
HKHarlan M. Krumholz
Harlan M. Krumholz